Financial Life Planners Takes $51,000 Position in Novo Nordisk A/S (NYSE:NVO)

Financial Life Planners bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 591 shares of the company’s stock, valued at approximately $51,000.

Several other hedge funds have also recently bought and sold shares of the business. Natixis Advisors LLC boosted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $86,000. Talbot Financial LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter worth $4,066,000. Finally, Zions Bancorporation N.A. boosted its position in Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 1.2 %

NVO stock opened at $84.36 on Monday. The firm has a fifty day moving average price of $93.56 and a two-hundred day moving average price of $112.87. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The firm has a market cap of $378.56 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.